Your browser doesn't support javascript.
loading
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde, Désirée; Cheng-Chung Wei, James; Dougados, Maxime; Mease, Philip; Deodhar, Atul; Maksymowych, Walter P; Van den Bosch, Filip; Sieper, Joachim; Tomita, Tetsuya; Landewé, Robert; Zhao, Fangyi; Krishnan, Eswar; Adams, David H; Pangallo, Beth; Carlier, Hilde.
Afiliação
  • van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: mail@dvanderheijde.nl.
  • Cheng-Chung Wei J; Institute of Medicine, Chung Shan Medical University, Department of Internal Medicine, Chung Shan Medical University Hospital, Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
  • Dougados M; Department of Rheumatology, Hôpital Cochin, Paris, France.
  • Mease P; Swedish Medical Center and University of Washington, Seattle, WA, USA.
  • Deodhar A; Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
  • Maksymowych WP; Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Van den Bosch F; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
  • Sieper J; Department of Rheumatology, Charite University Hospital, Berlin, Germany.
  • Tomita T; Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Landewé R; Amsterdam Rheumatology and Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland Medical Center, Heerlen, Netherlands.
  • Zhao F; Eli Lilly and Company, Indianapolis, IN, USA.
  • Krishnan E; Eli Lilly and Company, Indianapolis, IN, USA.
  • Adams DH; Eli Lilly and Company, Indianapolis, IN, USA.
  • Pangallo B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Carlier H; Eli Lilly and Company, Indianapolis, IN, USA.
Lancet ; 392(10163): 2441-2451, 2018 12 08.
Article em En | MEDLINE | ID: mdl-30360964
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Interleucina-17 / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Interleucina-17 / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article